Health Catalyst Yönetim
Yönetim kriter kontrolleri 3/4
Health Catalyst CEO'su Dan Burton, Oct2012 tarihinde atandı, in görev süresi 12.08 yıldır. şirketin hisselerinin 1.42% doğrudan sahiptir ve bu hisselerin değeri $ 7.02M dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.2 yıl ve 7.5 yıldır.
Anahtar bilgiler
Dan Burton
İcra Kurulu Başkanı
n/a
Toplam tazminat
| CEO maaş yüzdesi | n/a |
| CEO görev süresi | 12.1yrs |
| CEO sahipliği | 1.4% |
| Yönetim ortalama görev süresi | 2.2yrs |
| Yönetim Kurulu ortalama görev süresi | 7.5yrs |
Son yönetim güncellemeleri
Recent updates
Health Catalyst: Still Optimistic On Achieving Adjusted EBITDA Targets
Sep 24Health Catalyst, Inc.'s (NASDAQ:HCAT) Shares Lagging The Industry But So Is The Business
Jul 17
Health Catalyst: Stellar Earnings Growth Projected
Jun 26Health Catalyst, Inc. (NASDAQ:HCAT) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
May 12Benign Growth For Health Catalyst, Inc. (NASDAQ:HCAT) Underpins Its Share Price
Apr 04Health Catalyst: Achieving FY28 Long-Term Guidance Is Possible
Mar 09Health Catalyst Looks To Slim Down As It Faces Industry Headwinds (Downgrade)
Feb 16Is Health Catalyst (NASDAQ:HCAT) A Risky Investment?
Jan 27What Health Catalyst, Inc.'s (NASDAQ:HCAT) 25% Share Price Gain Is Not Telling You
Dec 24Is Health Catalyst, Inc. (NASDAQ:HCAT) Trading At A 47% Discount?
Dec 15Is Health Catalyst (NASDAQ:HCAT) Weighed On By Its Debt Load?
Oct 24Subdued Growth No Barrier To Health Catalyst, Inc.'s (NASDAQ:HCAT) Price
Jul 31Is Health Catalyst (NASDAQ:HCAT) Using Too Much Debt?
Jun 27Is Health Catalyst (NASDAQ:HCAT) Using Too Much Debt?
Feb 22Health Catalyst, Inc. (NASDAQ:HCAT) Shares Could Be 22% Above Their Intrinsic Value Estimate
Dec 06Is Health Catalyst (NASDAQ:HCAT) Using Debt In A Risky Way?
Nov 03Health Catalyst: Looking For A Turnaround For This 'Bio Boom' Candidate
Oct 14Health Catalyst names Kevin Freeman as Chief Growth Officer, Tarah Bryan as Chief Marketing Officer, Dave Ross as Chief Technology Officer
Sep 07CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$79m |
| Jun 30 2024 | n/a | n/a | -US$86m |
| Mar 31 2024 | n/a | n/a | -US$106m |
| Dec 31 2023 | n/a | n/a | -US$118m |
| Sep 30 2023 | n/a | n/a | -US$124m |
| Jun 30 2023 | n/a | n/a | -US$147m |
| Mar 31 2023 | n/a | n/a | -US$148m |
| Dec 31 2022 | US$4m | US$150k | -US$137m |
| Sep 30 2022 | n/a | n/a | -US$151m |
| Jun 30 2022 | n/a | n/a | -US$145m |
| Mar 31 2022 | n/a | n/a | -US$147m |
| Dec 31 2021 | US$6m | US$300k | -US$153m |
| Sep 30 2021 | n/a | n/a | -US$147m |
| Jun 30 2021 | n/a | n/a | -US$135m |
| Mar 31 2021 | n/a | n/a | -US$126m |
| Dec 31 2020 | US$5m | US$315k | -US$115m |
| Sep 30 2020 | n/a | n/a | -US$86m |
| Jun 30 2020 | n/a | n/a | -US$99m |
| Mar 31 2020 | n/a | n/a | -US$181m |
| Dec 31 2019 | US$4m | US$350k | -US$241m |
| Sep 30 2019 | n/a | n/a | -US$304m |
| Jun 30 2019 | n/a | n/a | -US$282m |
| Mar 31 2019 | n/a | n/a | -US$190m |
| Dec 31 2018 | US$5m | US$315k | -US$114m |
Tazminat ve Piyasa: Dan şirketinin toplam tazminatının US pazarındaki benzer büyüklükteki şirketlerle karşılaştırıldığında makul olup olmadığını tespit etmek için yeterli veri yok.
Tazminat ve Kazançlar: Dan 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.
CEO
Dan Burton (49 yo)
12.1yrs
Görev süresi
Mr. Daniel D. Burton, also known as Dan, has been the Chief Executive Officer of Health Catalyst, Inc. since October 2012 and has been its Director since September 2011. Mr. Burton has strategy and leaders...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO & Director | 12.1yrs | Veri yok | 1.42% $ 7.0m | |
| Chief Financial Officer | less than a year | US$823.62k | 0.19% $ 927.7k | |
| General Counsel & Secretary of the Board | 1.5yrs | US$946.31k | 0.17% $ 820.6k | |
| Chief People Officer | 6.8yrs | US$1.06m | 0.026% $ 130.4k | |
| Chief Operating Officer | less than a year | Veri yok | 0.051% $ 254.1k | |
| Chief Technology Officer | 2.2yrs | Veri yok | Veri yok | |
| Senior Vice President of Investor Relations and Financial Planning & Analysis | 3.8yrs | Veri yok | Veri yok | |
| Senior Vice President of Marketing & Communications | less than a year | Veri yok | Veri yok | |
| Chief Strategy Officer & Senior VP of Corporate Development | no data | Veri yok | Veri yok | |
| Senior Vice President of International | 5.5yrs | Veri yok | Veri yok | |
| Senior VP & Chief Clinical Officer | no data | Veri yok | Veri yok | |
| Chief Client Success Officer | no data | Veri yok | Veri yok |
2.2yrs
Ortalama Görev Süresi
46yo
Ortalama Yaş
Deneyimli Yönetim: HCAT 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.2 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO & Director | 13.2yrs | Veri yok | 1.42% $ 7.0m | |
| Independent Chairman | 8.8yrs | US$316.16k | 0.18% $ 895.8k | |
| Independent Director | 4.8yrs | US$233.49k | 0.076% $ 377.1k | |
| Independent Director | 4.8yrs | US$237.25k | 0.073% $ 363.1k | |
| Independent Director | 8.6yrs | US$244.77k | 0.058% $ 288.6k | |
| Independent Director | 7.5yrs | US$244.77k | 0.092% $ 456.4k | |
| Independent Director | 1.3yrs | Veri yok | Veri yok |
7.5yrs
Ortalama Görev Süresi
60yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: HCAT 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.5 yıldır).